Why the study?
Do small molecule kinase inhibitors reduce doxorubicin-induced inflammatory mediators in preclinical mouse models?
Population
Mouse primary macrophages cultured from ZAK-deficient mice, and in vivo mouse models
Comparison
Small molecule kinase inhibitors co-administered… vs Doxorubicin alone
Design
Preclinical
Authors
Loading...
May blunt doxorubicin inflammation in mice; leaves open clinical testing for cardiotoxicity prevention.
Do small molecule kinase inhibitors reduce doxorubicin-induced inflammatory mediators in preclinical mouse models?
Small molecule kinase inhibitors block ZAK-dependent inflammatory pathways induced by doxorubicin, suggesting a potential mechanism to mitigate chemotherapy-induced cardiotoxicity.
Wong et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: